FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
67 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS L. Stingeni1, L. Eichenfield2, J. Ornelas3, V. Prajapati4, C. Yang5, A. Tanaka6, S. Weidinger7, C. Flohr8, E. Swanson9, L. Martin10, S. Daveiga11, R. Gontijo Lima11, H. Elmaraghy11, E. Pierce11, P. Sen11, G. Gallo11, M. Piruzeli11, A. Larkin11, M. Grau12, Y. Mihaylov12, A. Paller13 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA; 3Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, USA; 4Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, Canada; 5Chang Gung University College of Medicine, Taoyuan, Taiwan; 6Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; 7Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Lübeck, Germany; 8Department of Dermatology and Population Health Sciences, King’s College London, UK; 9Ada West Dermatology, St Luke’s Children’s Hospital Idaho, USA; 10School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney, Australia; 11Eli Lilly and Company, Indianapolis, Indiana, USA; 12Almirall R&D, S.A., Barcelona, Spain; 13Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
0PDF: 0 -
10 | LEBRIKIZUMAB PROVIDES CLINICALLY MEANINGFUL RESPONSE IN FACE AND HANDS IN ADULTS AND ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ADHOPE 1 STUDY L. Stingeni1, C. Vestergaard2, J. Seneschal3|4, S. Weidinger5, A. Wollenberg6|7|8, A. Irvine9, H. Agell10, J. Valls Bancells10, V. Sapena10, D. Thaçi7 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Dermatology, University of Bordeaux, Bordeaux, France; 4Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, Bordeaux, France; 5Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany; 6University Medical Center of Augsburg, Augsburg, Germany; 7Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 8Department of Dermatology and Allergology, LMU Hospital, Munich, Germany; 9Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 10Almirall S.A., Barcelona, Spain
0PDF: 0 -
12 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS L. Stingeni1, L. Eichenfield2, J. Ornelas3, V. Prajapati4, C. Yang5, A. Tanaka6, S. Weidinger7, C. Flohr8, E. Swanson9, L. Martin10, S. Daveiga11, R. Gontijo Lima11, H. Elmaraghy11, E. Pierce11, P. Sen11, G. Gallo11, M. Piruzeli11, A. Larkin11, M. Grau12, Y. Mihaylov12, A. Paller13 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, US; 3Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, US; 4Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, CA; 5Chang Gung University College of Medicine, Taoyuan, TW; 6Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JP; 7Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, DE; 8Department of Dermatology and Population Health Sciences, King’s College London, London, UK; 9Ada West Dermatology, St Luke's Children's Hospital, Idaho, US; 10School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney AU; 11Eli Lilly and Company, Indianapolis, Indiana,US; 12Almirall R&D, S.A., Barcelona, ES; 13Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, US
0PDF: 0 -
11 | EFFICACY AND SAFETY OF LEBRIKIZUMAB IS MAINTAINED UP TO 4 YEARS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: FIRST YEAR OF ADLONG LONG-TERM EXTENSION TRIAL L. Stingeni1, S. Weidinger2, A. Irvine3, D. Thaçi4, J. Szepietowski5, T. Biedermann6, H. Agell7, Y. Mihaylov7, B. Kostov7, R. Coll7, W. Romero8, K. Reich9 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 3Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 4Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 5Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wrocław University of Science and Technology, Wrocław, Poland; 6Department of Dermatology and Allergy, Technical University of Munich, School of Medicine and Health, Munich, Germany; 7Almirall S.A., Barcelona, Spain; 8Eli Lilly and Company, Indianapolis, IN, USA; 9Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
0PDF: 0 -
30 | ATOPIC DERMATITIS AND ULCERATIVE COLITIS: A CASE REPORT ON THE MANAGEMENT OF OVERLAPPING COMORBIDITIES S. Senatore1, C. Cardinali1, A. Pieraccini2, F. Taviti1 | 1SOC Dermatologia Pistoia-Prato, USL Toscana Centro, Italy; 2SOC Gastroenterologia ed Endoscopia, USL Toscana Centro, Italy
0PDF: 0
1 - 7 of 7 items
